• Salvador Gutiérrez-Igual, Rut Lucas-Domínguez, Alberto Martí Rodrigo, Isabel Romero Crespo, and M Carmen Montesinos Mezquita.
• Servicios Asistenciales Farmacéuticos y Formación, Muy Ilustre Colegio Oficial de Farmacéuticos de Valencia (MICOF), Valencia, España; Departamento de Farmacología, Universidad de Valencia (UV), Burjassot, España. Electronic address: salvador.gutierrez@micof.es.
• Aten Primaria. 2024 May 1; 56 (5): 102836102836.

ObjectiveTo analyze, using the medication review program, Revisem®, the prevalence of drug-related problems (DRP) in patients in the province of Valencia who were on active treatment with proton pump inhibitors (PPI) in 2022.DesignDescriptive and retrospective observational study.Material And MethodsThe pharmacotherapeutic history of 295 patients was analyzed following the criteria proposed by the Pharmaceutical Care Network Europe, using the Revisem® digital platform of the Muy Ilustre Colegio Oficial de Farmacéuticos (MICOF).ResultsThe mean age of the patients was 81.8 ± 11.1 years and 66.4% were women. At least one DRP was detected in 97.3% of patients. 46.9% of the DRP analyzed were interactions, of which 29.7% involved a PPI, with omeprazole being the most frequent. DRPs with PPI are significantly related to certain patient conditions and pharmacological groups, such as female sex, age over 54 years and polypharmacy.ConclusionsThe application of the Revisem® digital platform allows the detection of a high prevalence of DRP at the provincial level. The application of new technological tools to detect the prevalence of DRP is essential to optimize patient treatments.Copyright © 2023 The Authors. Publicado por Elsevier España S.L.U. All rights reserved.

20 keywords...

hide…